- Home
- FIEE vs IMNN Comparison
FIEE vs IMNN Comparison
Compare FIEE & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIEE
- IMNN
- Stock Information
- Founded
- FIEE N/A
- IMNN 1982
- Country
- FIEE United States
- IMNN United States
- Employees
- FIEE 43
- IMNN N/A
- Industry
- FIEE Telecommunications Equipment
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- FIEE Utilities
- IMNN Health Care
- Exchange
- FIEE Nasdaq
- IMNN Nasdaq
- Market Cap
- FIEE 15.6M
- IMNN 12.9M
- IPO Year
- FIEE N/A
- IMNN 1985
- Fundamental
- Price
- FIEE $1.79
- IMNN $3.95
- Analyst Decision
- FIEE
- IMNN Buy
- Analyst Count
- FIEE 0
- IMNN 2
- Target Price
- FIEE N/A
- IMNN $182.61
- AVG Volume (30 Days)
- FIEE N/A
- IMNN 66.0K
- Earning Date
- FIEE N/A
- IMNN 11-13-2025
- Dividend Yield
- FIEE N/A
- IMNN N/A
- EPS Growth
- FIEE N/A
- IMNN N/A
- EPS
- FIEE N/A
- IMNN N/A
- Revenue
- FIEE N/A
- IMNN N/A
- Revenue This Year
- FIEE N/A
- IMNN N/A
- Revenue Next Year
- FIEE N/A
- IMNN N/A
- P/E Ratio
- FIEE N/A
- IMNN N/A
- Revenue Growth
- FIEE N/A
- IMNN N/A
- 52 Week Low
- FIEE N/A
- IMNN $3.64
- 52 Week High
- FIEE N/A
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- FIEE 22.94
- IMNN 36.55
- Support Level
- FIEE $1.50
- IMNN $3.64
- Resistance Level
- FIEE $2.63
- IMNN $4.38
- Average True Range (ATR)
- FIEE 0.18
- IMNN 0.30
- MACD
- FIEE -0.08
- IMNN 0.01
- Stochastic Oscillator
- FIEE 13.69
- IMNN 23.37
About FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).